S. Vijayarangan1, G. Rajaram2, B. Sharmila3
To compare the efficacy and tolerability of solifenacin and tolterodine in overactive bladder.
MATERIALS & METHODS
It is an open label, comparative, randomised, parallel group and prospective study. 30 patients suffering from overactive bladder were divided into two groups. They were randomised to receive either solifenacin (5 mg once daily) or tolterodine (2 mg twice daily) for 4 weeks. At baseline, 2 weeks and 4 weeks they were assessed for average number of micturition episodes, urgency episodes, incontinence episodes, urgency episodes, incontinence episodes and volume voided per void. The number of nocturia episodes was also assessed. Global efficacy and tolerability were also assessed by patients and urologists. Adverse effect profile was also analysed.
Comparing the end point value of solifenacin and tolterodine groups, there was significant improvement in symptoms like frequency (P<0.001), urgency (P<0.05), incontinence (P<0.05), volume voided per void (P<0.05) and nocturia (P<0.05), efficacy (P<0.05) and tolerability were also favourable for solifenacin.
Solifenacin 5 mg once daily is effective and well tolerated than tolterodine 2 mg twice a day in the management of overactive bladder. Solifenacin is also better tolerated.